

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of July 2018**

Commission File Number: **001-32001**

**Aptose Biosciences Inc.**

(Translation of registrant's name into English)

251 Consumers Road, Suite 1105 Toronto, Ontario M2J 4R3 Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [  ] Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

On July 24, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) [Exhibit 99.1](#). Press release dated July 24, 2018

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Aptose Biosciences Inc.**  
(Registrant)

Date: July 24, 2018

/s/ Gregory K. Chow  
Gregory K. Chow  
Senior Vice President and Chief Financial Officer

**Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018**

SAN DIEGO and TORONTO, July 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2018 on Tuesday, August 7, 2018 at 5:00 pm Eastern time.

***Conference Call & Webcast:******Tuesday, August 7, 2018 @ 5:00 pm Eastern time***

Toll-Free: (844) 882-7834  
International: (574) 990-9707  
Passcode: 2693419  
Webcast: <https://edge.media-server.com/m6/p/8qrt4qyn>

***Replays available through August 14, 2018***

Toll-Free: (855) 859-2056  
Replay Passcode: 2693419

The live conference call can also be accessed through a link on the Investor Relations section of Aptose's website at [ir.aptose.com](http://ir.aptose.com). Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company's website for 30 days.

The press release, the financial statements and the management's discussion and analysis for the quarter ended June 30, 2018 will be available on SEDAR at [www.sedar.com](http://www.sedar.com) and EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml)

**About Aptose Biosciences Inc.**

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage inhibitor of MYC oncogene expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor expected to reach IND submission by the end of 2018 and is planned for development to treat AML and certain B cell malignancies. For further information, please visit [www.aptose.com](http://www.aptose.com).

For further information, please contact:

**Aptose Biosciences**

Greg Chow, CFO  
647-479-9828  
Email: [gchow@aptose.com](mailto:gchow@aptose.com)

**SMP Communications**

Susan Pietropaolo  
201-923-2049  
[susan@smpcommunications.com](mailto:susan@smpcommunications.com)

**LifeSci Advisors**

Michael Wood  
Managing Director  
646-597-6983  
[mwood@lifesciadvisors.com](mailto:mwood@lifesciadvisors.com)